Swine H1N1 Neuraminidase Antibody | 5249

Swine H1N1 Neuraminidase Antibody | 5249 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Virus

Homology: N/A

Immunogen: Neuraminidase antibody was raised against a synthetic peptide from the novel swine influenza Neuraminidase protein.
This antibody is a cognate pair with product 5247.
The immunogen is located within amino acids 50 - 100 of Swine H1N1 Neuraminidase.

Research Area: Infectious Disease

Tested Application: E

Application: Neuraminidase antibody can be used for the detection of the Neuraminidase protein from the H1N1 strain of swine influenza A in ELISA. It will detect 2 ng of free peptide at 1 μg/mL

Specificiy: This antibody is specific for the novel swine influenza Neuraminidase and will not recognize the corresponding Neuraminidase sequence from the seasonal H1N1 influenza (A/Georgia/20/2006 (H1N1) ) . Will not cross-react with peptide corresponding to the seasonal influenza (H1N1) Neuraminidase.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Swine H1N1 Neuraminidase Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Swine H1N1 Neuraminidase Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: Swine H1N1 Neuraminidase antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Swine H1N1 Neuraminidase Antibody:

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Swine H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.